IONS Strangle Strategy
IONS (Ionis Pharmaceuticals, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapies within the United States. Its commercial portfolio includes three key medications: SPINRAZA, prescribed for spinal muscular atrophy (SMA) in both children and adults; TEGSEDI, an injectable treatment targeting polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adult patients; and WAYLIVRA, which addresses familial chylomicronemia syndrome and familial partial lipodystrophy. Ionis also maintains a robust pipeline, with several drug candidates currently in Phase 3 clinical trials. These include Eplontersen, a monthly self-administered subcutaneous injection designed for all forms of TTR amyloidosis; Olezarsen, intended for individuals with severe hypertriglyceridemia (SHTG); Donidalorsen, for patients suffering from hereditary angioedema; ION363, aimed at amyotrophic lateral sclerosis (ALS); Pelacarsen, developed for those with established cardiovascular disease and elevated lipoprotein(a); and Tofersen, which works by inhibiting the production of superoxide dismutase 1. Beyond these late-stage assets, the company is actively researching treatments for metabolic, infectious, renal, and ophthalmic diseases, as well as various types of cancer. The firm engages in significant collaborations, notably a strategic partnership with Biogen Inc.
IONS (Ionis Pharmaceuticals, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $13.42B, a beta of 0.37 versus the broader market, a 52-week range of 39.37-86.74, average daily share volume of 1.8M, a public-listing history dating back to 1991, approximately 1K full-time employees. These structural characteristics shape how IONS stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.37 indicates IONS has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a strangle on IONS?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current IONS snapshot
As of June 29, 2026, spot at $80.94, ATM IV 39.60%, IV rank 3.94%, expected move 11.35%. The strangle on IONS below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 18-day expiry.
Why this strangle structure on IONS specifically: IONS IV at 39.60% is on the cheap side of its 1-year range, which favors premium-buying structures like a IONS strangle, with a market-implied 1-standard-deviation move of approximately 11.35% (roughly $9.19 on the underlying). The 18-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated IONS expiries trade a higher absolute premium for lower per-day decay. Position sizing on IONS should anchor to the underlying notional of $80.94 per share and to the trader's directional view on IONS stock.
IONS strangle setup
The IONS strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With IONS near $80.94, the first option leg uses a $85.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed IONS chain at a 18-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 IONS shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $85.00 | $1.60 |
| Buy 1 | Put | $77.50 | $1.20 |
IONS strangle risk and reward
- Net Premium / Debit
- -$280.00
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- -$280.00
- Breakeven(s)
- $74.70, $87.80
- Risk / Reward Ratio
- Unbounded
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
IONS strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on IONS. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | +$7,469.00 |
| $17.91 | -77.9% | +$5,679.48 |
| $35.80 | -55.8% | +$3,889.96 |
| $53.70 | -33.7% | +$2,100.45 |
| $71.59 | -11.6% | +$310.93 |
| $89.49 | +10.6% | +$168.59 |
| $107.38 | +32.7% | +$1,958.11 |
| $125.28 | +54.8% | +$3,747.62 |
| $143.17 | +76.9% | +$5,537.14 |
| $161.07 | +99.0% | +$7,326.66 |
When traders use strangle on IONS
Strangles on IONS are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the IONS chain.
IONS thesis for this strangle
The market-implied 1-standard-deviation range for IONS extends from approximately $71.75 on the downside to $90.13 on the upside. A IONS long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current IONS IV rank near 3.94% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on IONS at 39.60%. As a Healthcare name, IONS options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to IONS-specific events.
IONS strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. IONS positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move IONS alongside the broader basket even when IONS-specific fundamentals are unchanged. Always rebuild the position from current IONS chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on IONS?
- A strangle on IONS is the strangle strategy applied to IONS (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With IONS stock trading near $80.94, the strikes shown on this page are snapped to the nearest listed IONS chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are IONS strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the IONS strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 39.60%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$280.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a IONS strangle?
- The breakeven for the IONS strangle priced on this page is roughly $74.70 and $87.80 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current IONS market-implied 1-standard-deviation expected move is approximately 11.35%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on IONS?
- Strangles on IONS are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the IONS chain.
- How does current IONS implied volatility affect this strangle?
- IONS ATM IV is at 39.60% with IV rank near 3.94%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.